Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Jie Wu, Yu-Chen Wang, Wen-Hao Xu, Wen-Jie Luo, Fang-Ning Wan, Hai-Liang Zhang, Ding-Wei Ye, Yuan-Yuan Qu & Yi-Ping Zhu. (2020) High Expression of CD39 is Associated with Poor Prognosis and Immune Infiltrates in Clear Cell Renal Cell Carcinoma. OncoTargets and Therapy 13, pages 10453-10464.
Read now
Read now
Articles from other publishers (18)
Shumin Xu, Chenyang Wang, Lingge Yang, Jiaji Wu, Mengshu Li, Peng Xiao, Zhiyong Xu, Yun Xu & Kai Wang. (2023) Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy. Frontiers in Immunology 14.
Crossref
Crossref
Xuan Jiang, Xiaofang Wu, Yuxi Xiao, Penglin Wang, Jiamian Zheng, Xiuli Wu & Zhenyi Jin. (2023) The ectonucleotidases CD39 and CD73 on T cells: The new pillar of hematological malignancy. Frontiers in Immunology 14.
Crossref
Crossref
Vitória Brum da Silva Nunes, Camila Kehl Dias, Marco Antônio De Bastiani, Mariela Granero Farias, Fabiane Spagnol, Ana Paula Alegretti, Liane Esteves Daudt, Mariana Bohns Michalowski, Ana Maria Oliveira Battastini, Alessandra Aparecida Paz & Fabrício Figueiró. (2022) NT5E gene and CD38 protein as potential prognostic biomarkers for childhood B-acute lymphoblastic leukemia. Purinergic Signalling 18:2, pages 211-222.
Crossref
Crossref
Fernanda Cardoso da Silva, Angelo Borges de Melo Neto, Christina Aparecida Martins, Thaís Cunha de Sousa Cardoso, Matheus de Souza Gomes, Thaise Gonçalves de Araújo & Cristina Ribas Fürstenau. (2021) Is the regulation by miRNAs of NTPDase1 and ecto-5’-nucleotidase genes involved with the different profiles of breast cancer subtypes?. Purinergic Signalling 18:1, pages 123-133.
Crossref
Crossref
Jun-hua Luo, Yun-hua Zhu & Cheng Xiang. (2021) Favorable function of Ectonucleoside triphosphate diphosphohydrolase 1 high expression in thyroid carcinoma. Hereditas 158:1.
Crossref
Crossref
Elham Baghbani, Saeed Noorolyai, Dariush Shanehbandi, Ahad Mokhtarzadeh, Leili Aghebati-Maleki, Vahid Khaze Shahgoli, Oronzo Brunetti, Shima Rahmani, Mahdi Abdoli Shadbad, Amir Baghbanzadeh, Nicola Silvestris & Behzad Baradaran. (2021) Regulation of immune responses through CD39 and CD73 in cancer: Novel checkpoints. Life Sciences 282, pages 119826.
Crossref
Crossref
Anna M. Chiarella, Yun K. Ryu, Gulam A. Manji & Anil K. Rustgi. (2021) Extracellular ATP and Adenosine in Cancer Pathogenesis and Treatment. Trends in Cancer 7:8, pages 731-750.
Crossref
Crossref
Kamylla Fernanda Souza de Souza, Luciana Rocha Costa, Edgar J. Paredes-Gamero & Jeandre Augusto dos Santos Jaques. 2021. Sinalização purinérgica: implicações fisiopatológicas. Sinalização purinérgica: implicações fisiopatológicas
190
210
.
Yasuhiro Nagate, Sachiko Ezoe, Jiro Fujita, Daisuke Okuzaki, Daisuke Motooka, Tomohiko Ishibashi, Michiko Ichii, Akira Tanimura, Masako Kurashige, Eiichi Morii, Takuya Fukushima, Youko Suehiro, Takafumi Yokota, Hirohiko Shibayama, Kenji Oritani & Yuzuru Kanakura. (2020) Ectonucleotidase CD39 is highly expressed on ATLL cells and is responsible for their immunosuppressive function. Leukemia 35:1, pages 107-118.
Crossref
Crossref
Rui Yang, Samah Elsaadi, Kristine Misund, Pegah Abdollahi, Esten Nymoen Vandsemb, Siv Helen Moen, Anna Kusnierczyk, Geir Slupphaug, Therese Standal, Anders Waage, Tobias S Slørdahl, Torstein Baade Rø, Even Rustad, Anders Sundan, Carl Hay, Zachary Cooper, Alwin G Schuller, Richard Woessner, Alexandra Borodovsky, Eline Menu, Magne Børset & Anne Marit Sponaas. (2020) Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade. Journal for ImmunoTherapy of Cancer 8:1, pages e000610.
Crossref
Crossref
Tina Vosoughi, Marziye Bagheri, Mehran Hosseinzadeh, Ali Ehsanpour, Nader Davari & Najmaldin Saki. (2019) CD markers variations in chronic lymphocytic leukemia: New insights into prognosis. Journal of Cellular Physiology 234:11, pages 19420-19439.
Crossref
Crossref
Tiziana Vaisitti, Francesca Arruga, Giulia Guerra & Silvia Deaglio. (2019) Ectonucleotidases in Blood Malignancies: A Tale of Surface Markers and Therapeutic Targets. Frontiers in Immunology 10.
Crossref
Crossref
Akil Hammami, David Allard, Bertrand Allard & John Stagg. (2019) Targeting the adenosine pathway for cancer immunotherapy. Seminars in Immunology 42, pages 101304.
Crossref
Crossref
Yi Huang, Zili Gu, Yang Fan, Guangxi Zhai, Xiaogang Zhao, Qifeng Sun, Yanbin Shi & Guimei Lin. (2019) Inhibition of the adenosinergic pathway: the indispensable part of oncological therapy in the future. Purinergic Signalling 15:1, pages 53-67.
Crossref
Crossref
Tiziana Vaisitti, Francesca Arruga & Silvia Deaglio. (2018) Targeting the Adenosinergic Axis in Chronic Lymphocytic Leukemia: A Way to Disrupt the Tumor Niche?. International Journal of Molecular Sciences 19:4, pages 1167.
Crossref
Crossref
Dipti Vijayan, Mark J. Smyth & Michele W. L. Teng. 2018. Oncoimmunology. Oncoimmunology
115
141
.
Dipti Vijayan, Arabella Young, Michele W.L. Teng & Mark J. Smyth. (2017) Targeting immunosuppressive adenosine in cancer. Nature Reviews Cancer 17:12, pages 709-724.
Crossref
Crossref
David Allard, Bertrand Allard, Pierre-Olivier Gaudreau, Pavel Chrobak & John Stagg. (2016) CD73–adenosine: a next-generation target in immuno-oncology. Immunotherapy 8:2, pages 145-163.
Crossref
Crossref